Premium
Immuneering Corporation (IMRX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and no... Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.36 | -24.0282685512 | 5.66 | 5.6794 | 4.2008 | 3175943 | 4.44644495 | CS |
| 4 | -0.94 | -17.9389312977 | 5.24 | 6.89 | 4.2008 | 2224624 | 4.98720253 | CS |
| 12 | -0.76 | -15.0197628458 | 5.06 | 6.89 | 4.2008 | 1244712 | 5.13455289 | CS |
| 26 | -2.1 | -32.8125 | 6.4 | 8.48 | 4.04 | 1405697 | 5.30824494 | CS |
| 52 | 2.12 | 97.247706422 | 2.18 | 10.08 | 1.66 | 1545461 | 5.40060752 | CS |
| 156 | -5.73 | -57.1286141575 | 10.03 | 11.92 | 1 | 1371335 | 3.46458007 | CS |
| 260 | 4.2476 | 8106.10687023 | 0.0524 | 33.99 | 0.0524 | 853183 | 3.81250905 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
